EMP2 and neoplasm: The correlation between EMP2 upregulation, taxane resistance, and poor overall survival, coupled with the promising results of anti-EMP2 mAbs in reducing tumor burden, underscore the potential of targeting EMP2 to manage taxane-resistant TNBC.